Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
(NASDAQ: TSHA) Delayed: 5.02 -0.14 (2.71%)
Previous Close $5.16    52 Week High $ 
Open $5.16    52 Week Low $ 
Day High $5.28    P/E N/A 
Day Low $4.96    EPS $ 
Volume 9,116,677       

(NASDAQ: TSHA) Delayed: 5.02 -0.14 (2.71%)
Previous Close $5.16    52 Week High $ 
Open $5.16    52 Week Low $ 
Day High $5.28    P/E N/A 
Day Low $4.96    EPS $ 
Volume 9,116,677